 | • レポートコード：QY2207C3452 • 出版社/出版日：QYResearch / 2022年7月11日 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,087,800 (USD7,350) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症のパンデミックにより、世界の薬物誘発性腎毒性治療の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に薬物誘発性腎毒性治療の世界市場のxxx％を占める「ステロイド療法」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「製薬＆バイオテクノロジー企業」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の薬物誘発性腎毒性治療の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの薬物誘発性腎毒性治療市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの薬物誘発性腎毒性治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 薬物誘発性腎毒性治療のグローバル主要メーカーには、Roche Diagnostic Limited、Siemens Healthcare、Abbott Laboratories、Thermo Fisher Scientific、Agilent Technologies、Bio-Rad Laboratories、Aushon BioSystem、Epistem、G.E. Healthcare、Affymetrixなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 薬物誘発性腎毒性治療市場は、種類と用途によって区分されます。世界の薬物誘発性腎毒性治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 ステロイド療法、その他 【用途別セグメント】 製薬＆バイオテクノロジー企業、学術機関、研究機関、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 薬物誘発性腎毒性治療製品概要 - 種類別市場（ステロイド療法、その他） - 用途別市場（製薬＆バイオテクノロジー企業、学術機関、研究機関、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の薬物誘発性腎毒性治療販売量予測2017-2028 - 世界の薬物誘発性腎毒性治療売上予測2017-2028 - 薬物誘発性腎毒性治療の地域別販売量 - 薬物誘発性腎毒性治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別薬物誘発性腎毒性治療販売量 - 主要メーカー別薬物誘発性腎毒性治療売上 - 主要メーカー別薬物誘発性腎毒性治療価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（ステロイド療法、その他） - 薬物誘発性腎毒性治療の種類別販売量 - 薬物誘発性腎毒性治療の種類別売上 - 薬物誘発性腎毒性治療の種類別価格 ・用途別市場規模（製薬＆バイオテクノロジー企業、学術機関、研究機関、その他） - 薬物誘発性腎毒性治療の用途別販売量 - 薬物誘発性腎毒性治療の用途別売上 - 薬物誘発性腎毒性治療の用途別価格 ・北米市場 - 北米の薬物誘発性腎毒性治療市場規模（種類別、用途別） - 主要国別の薬物誘発性腎毒性治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの薬物誘発性腎毒性治療市場規模（種類別、用途別） - 主要国別の薬物誘発性腎毒性治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の薬物誘発性腎毒性治療市場規模（種類別、用途別） - 主要国別の薬物誘発性腎毒性治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の薬物誘発性腎毒性治療市場規模（種類別、用途別） - 主要国別の薬物誘発性腎毒性治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの薬物誘発性腎毒性治療市場規模（種類別、用途別） - 主要国別の薬物誘発性腎毒性治療市場規模（トルコ、サウジアラビア） ・企業情報 Roche Diagnostic Limited、Siemens Healthcare、Abbott Laboratories、Thermo Fisher Scientific、Agilent Technologies、Bio-Rad Laboratories、Aushon BioSystem、Epistem、G.E. Healthcare、Affymetrix ・産業チェーン及び販売チャネル分析 - 薬物誘発性腎毒性治療の産業チェーン分析 - 薬物誘発性腎毒性治療の原材料 - 薬物誘発性腎毒性治療の生産プロセス - 薬物誘発性腎毒性治療の販売及びマーケティング - 薬物誘発性腎毒性治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 薬物誘発性腎毒性治療の産業動向 - 薬物誘発性腎毒性治療のマーケットドライバー - 薬物誘発性腎毒性治療の課題 - 薬物誘発性腎毒性治療の阻害要因 ・主な調査結果 |
Market Analysis and Insights: Global Drug-induced Nephrotoxicity Treatment Market
The global Drug-induced Nephrotoxicity Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Steroid Therapy accounting for % of the Drug-induced Nephrotoxicity Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pharmaceutical and Biotechnology Companies segment is altered to an % CAGR throughout this forecast period.
China Drug-induced Nephrotoxicity Treatment market size is valued at US$ million in 2021, while the North America and Europe Drug-induced Nephrotoxicity Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Drug-induced Nephrotoxicity Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drug-induced Nephrotoxicity Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drug-induced Nephrotoxicity Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drug-induced Nephrotoxicity Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drug-induced Nephrotoxicity Treatment market.
Global Drug-induced Nephrotoxicity Treatment Scope and Market Size
Drug-induced Nephrotoxicity Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Drug-induced Nephrotoxicity Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Steroid Therapy
Others
Segment by Application
Pharmaceutical and Biotechnology Companies
Academic Institutes
Research Organizations
Others
By Company
Roche Diagnostic Limited
Siemens Healthcare
Abbott Laboratories
Thermo Fisher Scientific
Agilent Technologies
Bio-Rad Laboratories
Aushon BioSystem
Epistem
G.E. Healthcare
Affymetrix
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drug-induced Nephrotoxicity Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Steroid Therapy
1.2.3 Others
1.3 Market by Application
1.3.1 Global Drug-induced Nephrotoxicity Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Academic Institutes
1.3.4 Research Organizations
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drug-induced Nephrotoxicity Treatment Market Perspective (2017-2028)
2.2 Drug-induced Nephrotoxicity Treatment Growth Trends by Region
2.2.1 Drug-induced Nephrotoxicity Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Drug-induced Nephrotoxicity Treatment Historic Market Size by Region (2017-2022)
2.2.3 Drug-induced Nephrotoxicity Treatment Forecasted Market Size by Region (2023-2028)
2.3 Drug-induced Nephrotoxicity Treatment Market Dynamics
2.3.1 Drug-induced Nephrotoxicity Treatment Industry Trends
2.3.2 Drug-induced Nephrotoxicity Treatment Market Drivers
2.3.3 Drug-induced Nephrotoxicity Treatment Market Challenges
2.3.4 Drug-induced Nephrotoxicity Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug-induced Nephrotoxicity Treatment Players by Revenue
3.1.1 Global Top Drug-induced Nephrotoxicity Treatment Players by Revenue (2017-2022)
3.1.2 Global Drug-induced Nephrotoxicity Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Drug-induced Nephrotoxicity Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drug-induced Nephrotoxicity Treatment Revenue
3.4 Global Drug-induced Nephrotoxicity Treatment Market Concentration Ratio
3.4.1 Global Drug-induced Nephrotoxicity Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug-induced Nephrotoxicity Treatment Revenue in 2021
3.5 Drug-induced Nephrotoxicity Treatment Key Players Head office and Area Served
3.6 Key Players Drug-induced Nephrotoxicity Treatment Product Solution and Service
3.7 Date of Enter into Drug-induced Nephrotoxicity Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug-induced Nephrotoxicity Treatment Breakdown Data by Type
4.1 Global Drug-induced Nephrotoxicity Treatment Historic Market Size by Type (2017-2022)
4.2 Global Drug-induced Nephrotoxicity Treatment Forecasted Market Size by Type (2023-2028)
5 Drug-induced Nephrotoxicity Treatment Breakdown Data by Application
5.1 Global Drug-induced Nephrotoxicity Treatment Historic Market Size by Application (2017-2022)
5.2 Global Drug-induced Nephrotoxicity Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Drug-induced Nephrotoxicity Treatment Market Size (2017-2028)
6.2 North America Drug-induced Nephrotoxicity Treatment Market Size by Type
6.2.1 North America Drug-induced Nephrotoxicity Treatment Market Size by Type (2017-2022)
6.2.2 North America Drug-induced Nephrotoxicity Treatment Market Size by Type (2023-2028)
6.2.3 North America Drug-induced Nephrotoxicity Treatment Market Share by Type (2017-2028)
6.3 North America Drug-induced Nephrotoxicity Treatment Market Size by Application
6.3.1 North America Drug-induced Nephrotoxicity Treatment Market Size by Application (2017-2022)
6.3.2 North America Drug-induced Nephrotoxicity Treatment Market Size by Application (2023-2028)
6.3.3 North America Drug-induced Nephrotoxicity Treatment Market Share by Application (2017-2028)
6.4 North America Drug-induced Nephrotoxicity Treatment Market Size by Country
6.4.1 North America Drug-induced Nephrotoxicity Treatment Market Size by Country (2017-2022)
6.4.2 North America Drug-induced Nephrotoxicity Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Drug-induced Nephrotoxicity Treatment Market Size (2017-2028)
7.2 Europe Drug-induced Nephrotoxicity Treatment Market Size by Type
7.2.1 Europe Drug-induced Nephrotoxicity Treatment Market Size by Type (2017-2022)
7.2.2 Europe Drug-induced Nephrotoxicity Treatment Market Size by Type (2023-2028)
7.2.3 Europe Drug-induced Nephrotoxicity Treatment Market Share by Type (2017-2028)
7.3 Europe Drug-induced Nephrotoxicity Treatment Market Size by Application
7.3.1 Europe Drug-induced Nephrotoxicity Treatment Market Size by Application (2017-2022)
7.3.2 Europe Drug-induced Nephrotoxicity Treatment Market Size by Application (2023-2028)
7.3.3 Europe Drug-induced Nephrotoxicity Treatment Market Share by Application (2017-2028)
7.4 Europe Drug-induced Nephrotoxicity Treatment Market Size by Country
7.4.1 Europe Drug-induced Nephrotoxicity Treatment Market Size by Country (2017-2022)
7.4.2 Europe Drug-induced Nephrotoxicity Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size (2017-2028)
8.2 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Type
8.2.1 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Application
8.3.1 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Region
8.4.1 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Drug-induced Nephrotoxicity Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Drug-induced Nephrotoxicity Treatment Market Size (2017-2028)
9.2 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Type
9.2.1 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Drug-induced Nephrotoxicity Treatment Market Share by Type (2017-2028)
9.3 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Application
9.3.1 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Drug-induced Nephrotoxicity Treatment Market Share by Application (2017-2028)
9.4 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Country
9.4.1 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Drug-induced Nephrotoxicity Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size (2017-2028)
10.2 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Type
10.2.1 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Application
10.3.1 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Country
10.4.1 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Drug-induced Nephrotoxicity Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche Diagnostic Limited
11.1.1 Roche Diagnostic Limited Company Details
11.1.2 Roche Diagnostic Limited Business Overview
11.1.3 Roche Diagnostic Limited Drug-induced Nephrotoxicity Treatment Introduction
11.1.4 Roche Diagnostic Limited Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.1.5 Roche Diagnostic Limited Recent Developments
11.2 Siemens Healthcare
11.2.1 Siemens Healthcare Company Details
11.2.2 Siemens Healthcare Business Overview
11.2.3 Siemens Healthcare Drug-induced Nephrotoxicity Treatment Introduction
11.2.4 Siemens Healthcare Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.2.5 Siemens Healthcare Recent Developments
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Company Details
11.3.2 Abbott Laboratories Business Overview
11.3.3 Abbott Laboratories Drug-induced Nephrotoxicity Treatment Introduction
11.3.4 Abbott Laboratories Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.3.5 Abbott Laboratories Recent Developments
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Details
11.4.2 Thermo Fisher Scientific Business Overview
11.4.3 Thermo Fisher Scientific Drug-induced Nephrotoxicity Treatment Introduction
11.4.4 Thermo Fisher Scientific Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.4.5 Thermo Fisher Scientific Recent Developments
11.5 Agilent Technologies
11.5.1 Agilent Technologies Company Details
11.5.2 Agilent Technologies Business Overview
11.5.3 Agilent Technologies Drug-induced Nephrotoxicity Treatment Introduction
11.5.4 Agilent Technologies Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.5.5 Agilent Technologies Recent Developments
11.6 Bio-Rad Laboratories
11.6.1 Bio-Rad Laboratories Company Details
11.6.2 Bio-Rad Laboratories Business Overview
11.6.3 Bio-Rad Laboratories Drug-induced Nephrotoxicity Treatment Introduction
11.6.4 Bio-Rad Laboratories Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.6.5 Bio-Rad Laboratories Recent Developments
11.7 Aushon BioSystem
11.7.1 Aushon BioSystem Company Details
11.7.2 Aushon BioSystem Business Overview
11.7.3 Aushon BioSystem Drug-induced Nephrotoxicity Treatment Introduction
11.7.4 Aushon BioSystem Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.7.5 Aushon BioSystem Recent Developments
11.8 Epistem
11.8.1 Epistem Company Details
11.8.2 Epistem Business Overview
11.8.3 Epistem Drug-induced Nephrotoxicity Treatment Introduction
11.8.4 Epistem Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.8.5 Epistem Recent Developments
11.9 G.E. Healthcare
11.9.1 G.E. Healthcare Company Details
11.9.2 G.E. Healthcare Business Overview
11.9.3 G.E. Healthcare Drug-induced Nephrotoxicity Treatment Introduction
11.9.4 G.E. Healthcare Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.9.5 G.E. Healthcare Recent Developments
11.10 Affymetrix
11.10.1 Affymetrix Company Details
11.10.2 Affymetrix Business Overview
11.10.3 Affymetrix Drug-induced Nephrotoxicity Treatment Introduction
11.10.4 Affymetrix Revenue in Drug-induced Nephrotoxicity Treatment Business (2017-2022)
11.10.5 Affymetrix Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer